207 related articles for article (PubMed ID: 37852529)
1. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials.
Karakasis P; Patoulias D; Pamporis K; Stachteas P; Bougioukas KI; Klisic A; Fragakis N; Rizzo M
Metabolism; 2023 Dec; 149():155710. PubMed ID: 37852529
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
[TBL] [Abstract][Full Text] [Related]
3. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
Ji Q
Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis.
Li H; Yu G; Huang Q; Yang B; Nie J; Liu Y; Tu X
Biomed Pharmacother; 2024 Feb; 171():116150. PubMed ID: 38242040
[TBL] [Abstract][Full Text] [Related]
5. The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.
Liu Y; Ruan B; Jiang H; Le S; Liu Y; Ao X; Huang Y; Shi X; Xue R; Fu X; Wang S
Am J Clin Nutr; 2023 Sep; 118(3):614-626. PubMed ID: 37661106
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis.
Fatima H; Rangwala HS; Mustafa MS; Shafique MA; Abbas SR; Rizwan A; Fadlalla Ahmed TK; Arshad A
Diabetes Metab Syndr Obes; 2023; 16():3567-3578. PubMed ID: 37954886
[TBL] [Abstract][Full Text] [Related]
8. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
[TBL] [Abstract][Full Text] [Related]
9. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Banerjee M; Pal R; Mukhopadhyay S; Nair K
J Clin Endocrinol Metab; 2023 Jun; 108(7):1806-1812. PubMed ID: 36800286
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
12. Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.
Patoulias D; Popovic DS; Stoian AP; Janez A; Sahebkar A; Rizzo M
J Diabetes Complications; 2023 Aug; 37(8):108529. PubMed ID: 37301063
[TBL] [Abstract][Full Text] [Related]
13. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Pratt E; Ma X; Liu R; Robins D; Coskun T; Sloop KW; Haupt A; Benson C
Diabetes Obes Metab; 2023 Sep; 25(9):2642-2649. PubMed ID: 37264711
[TBL] [Abstract][Full Text] [Related]
14. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.
Xie W; Hong Z; Li B; Huang B; Dong S; Cai Y; Ruan L; Xu Q; Mou L; Zhang Y
J Diabetes Complications; 2024 Jun; 38(6):108743. PubMed ID: 38688179
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus with Advanced and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.
Krisanapan P; Sanpawithayakul K; Pattharanitima P; Thongprayoon C; Miao J; Mao MA; Suppadungsuk S; Tangpanithandee S; Craici IM; Cheungpasitporn W
Diseases; 2024 Jan; 12(1):. PubMed ID: 38248365
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
17. Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Saxena AR; Frias JP; Gorman DN; Lopez RN; Andrawis N; Tsamandouras N; Birnbaum MJ
Diabetes Obes Metab; 2023 Oct; 25(10):2805-2814. PubMed ID: 37311722
[TBL] [Abstract][Full Text] [Related]
18. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.
Ma H; Lin YH; Dai LZ; Lin CS; Huang Y; Liu SY
BMJ Open; 2023 Mar; 13(3):e061807. PubMed ID: 36882248
[TBL] [Abstract][Full Text] [Related]
20. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Wharton S; Blevins T; Connery L; Rosenstock J; Raha S; Liu R; Ma X; Mather KJ; Haupt A; Robins D; Pratt E; Kazda C; Konig M;
N Engl J Med; 2023 Sep; 389(10):877-888. PubMed ID: 37351564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]